Sequana Medical NV: UK NICE raadt het gebruik aan van de alfapump® voor de behandeling van refractaire ascites veroorzaakt door cirrose onder bijzondere regelingen
November 15, 2018 01:00 ET
|
Sequana Medical
Een belegging in de aangeboden aandelen houdt substantiële risico's en onzekerheden in. Potentiële beleggers moeten het gehele Prospectus lezen dat zal worden voorbereid door de Vennootschap, en...
Sequana Medical NV: UK NICE recommends use of the alfapump® for the treatment of refractory ascites caused by cirrhosis under special arrangements
November 15, 2018 01:00 ET
|
Sequana Medical
An investment in the offered shares involves substantial risks and uncertainties. Prospective investors should read the entire Prospectus that will be prepared by the Company, and, in particular,...
Sequana Medical Kondigt de Benoeming aan van Sectorexperts Pierre Chauvineau als Voorzitter en Wim Ottevaere als Niet-Uitvoerend Bestuurder
November 08, 2018 01:02 ET
|
Sequana Medical
Een belegging in de aangeboden aandelen houdt substantiële risico's en onzekerheden in. Potentiële beleggers moeten het gehele Prospectus lezen dat zal worden voorbereid door de Vennootschap, en...
Sequana Medical Announces the Appointments of Industry Experts Pierre Chauvineau as Chairman and Wim Ottevaere as Non-Executive Director
November 08, 2018 01:02 ET
|
Sequana Medical
An investment in the offered shares involves substantial risks and uncertainties. Prospective investors should read the entire Prospectus that will be prepared by the Company, and, in particular,...
Sequana Medical Kondigt het Voornemen aan om een Eerste Openbaar Aanbod ("Initial Public Offering") te Lanceren op Euronext Brussel
November 08, 2018 01:00 ET
|
Sequana Medical
Een belegging in de aangeboden aandelen houdt substantiële risico's en onzekerheden in. Potentiële beleggers moeten het gehele Prospectus lezen dat zal worden voorbereid door de Vennootschap, en...
Sequana Medical Announces Intention to Launch an Initial Public Offering on Euronext Brussels
November 08, 2018 01:00 ET
|
Sequana Medical
An investment in the offered shares involves substantial risks and uncertainties. Prospective investors should read the entire Prospectus that will be prepared by the Company, and, in particular,...
Sequana Medical establishes new corporate headquarters in Ghent, Belgium and raises €8.5 million from leading Belgian investors including Newton Biocapital, PMV and SFPI-FPIM as well as existing shareholders
October 15, 2018 01:00 ET
|
Sequana Medical
Press Release Sequana Medical establishes new corporate headquarters in Ghent, Belgium and raises €8.5 million from leading Belgian investors includingNewton Biocapital, PMV and SFPI-FPIM as well as...
Sequana Medical reports positive data on use of the alfapump® in malignant ascites patients at the International Gynecologic Cancer Society
September 17, 2018 07:00 ET
|
Sequana Medical
Sequana Medical reports positive data on use of the alfapump® in malignant ascites patients at the International Gynecologic Cancer Society Data also to be presented at the 68th...
Sequana Medical presents pre-clinical proof of concept results of its Direct Sodium Removal (DSR) therapy for the management of volume overload in heart failure at the Annual Scientific Meeting of the Heart Failure Society
September 17, 2018 01:05 ET
|
Sequana Medical
Press Release Sequana Medical announces presentation of pre-clinical proof of concept results of its Direct Sodium Removal (DSR) therapy for the management of volume overload in heart failure at the...
Sequana Medical reports positive data on use of the alfapump® in malignant ascites patients at the International Gynecologic Cancer Society
September 17, 2018 01:00 ET
|
Sequana Medical
Press Release Sequana Medical reports positive data on use of the alfapump® in malignant ascites patients at the International Gynecologic Cancer Society Data also to be presented at...